Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy

被引：4
|
作者：
Xu, Binghe [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 09期
关键词：
D O I：
10.1016/S1470-2045(23)00361-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E357 / E357
页数：1
相关论文
共 50 条
  • [41] Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports
    Martos, Tamara
    Saint-Gerons, Marta
    Masfarre, Laura
    Castro-Henriques, Maria
    Martinez-Garcia, Maria
    Servitja, Sonia
    Albanell, Joan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [42] First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)
    Hoskins, Kent F.
    Richards, Paul
    Wisinski, Kari
    CANCER RESEARCH, 2018, 78 (13)
  • [43] Dalpiciclib and tucidinostat in patients with HR+/HER2-advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial
    Wang, Tao
    Zhou, Jinmei
    Wu, Xuexue
    Jiang, Zefei
    CANCER RESEARCH, 2024, 84 (09)
  • [44] CDK4/6 inhibitors in breast cancer: spotting the difference
    Jose Manuel Perez-Garcia
    Javier Cortes
    Antonio Llombart-Cussac
    Nature Medicine, 2021, 27 : 1868 - 1869
  • [45] The role of CDK4/6 inhibitors in early breast cancer
    Gil-Gil, Miguel
    Alba, Emilio
    Gavila, Joaquin
    de la Haba-Rodriguez, Juan
    Ciruelos, Eva
    Tolosa, Pablo
    Candini, Daniele
    Llombart-Cussac, Antonio
    BREAST, 2021, 58 : 160 - 169
  • [46] Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2-breast cancer in Mexico
    Molina-Jaimes, Mariana
    Galindo-Gonzalez, Antonio
    Verduzco-Aguirre, Haydee Cristina
    Bautista-Arredondo, Sergio
    Reyes-Teran, Gustavo
    Soto-Perez-de-Celis, Enrique
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (01): : 239 - 244
  • [47] Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2− breast cancer in Mexico
    Mariana Molina-Jaimes
    Antonio Galindo-González
    Haydeé Cristina Verduzco-Aguirre
    Sergio Bautista-Arredondo
    Gustavo Reyes-Terán
    Enrique Soto-Perez-de-Celis
    Clinical and Translational Oncology, 2024, 26 : 239 - 244
  • [48] CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update
    O'Sullivan, Ciara C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) : 1657 - 1667
  • [49] Determining Clinicopathologic Factors That Influence Treatment in Advanced Breast Cancer in Argentina After CDK4/6 Inhibitors
    Waisberg, Federico
    Mando, Pablo
    Almada, Carolina
    Kassis, Naima
    Mainella, Andrea
    Cermignani, Luciano
    Riggi, Maria Cecilia
    Winocur, Melina
    Gonzalez, Ramiro
    Guercovich, Andres
    Ayala, Natalia
    Micheri, Cristian
    Ituarte, Ana Carolina
    Mattos, Lucia Gonzalez
    Llugdar, Pamela
    Casalnuovo, Monica
    Lutteral, Maribel
    Cinquini, Sebastian
    Mazzotta, Alejandro
    Alcantara, Janeth Lara
    Penayo, Rosa
    Gomez-Abuin, Gonzalo
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [50] Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in Panama
    Castillo-Fernandez, Omar O.
    Lim, Maria
    Montano, Lilian
    CANCER RESEARCH, 2023, 83 (05)
12345